# SB-773812 Administered In Adults With Schizophrenia

> **NCT00259870** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 338 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SB-773812
- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT00259870
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 338 (ACTUAL)
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00259870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00259870, "SB-773812 Administered In Adults With Schizophrenia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00259870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*